Novo Nordisk A/S (NOV.DE)
Novo Nordisk A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Bagsvaerd, CR, DK. The stock last traded at $40.01, down 2.19% on the session, giving a market capitalisation of $177.72B. Its beta of 0.35 implies it has historically moved less than the broad market.
Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian territories, including Mainland China, Hong Kong, and Taiwan. The company's activities are divided into two main categories: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division offers therapeutic solutions for conditions such as diabetes, obesity, cardiovascular health, and other developing medical areas. Meanwhile, the Rare Disease division provides treatments for unusual blood conditions, uncommon endocrine disorders, and hormone replacement therapies. Beyond its drug portfolio, Novo Nordisk also manufactures medical devices like insulin pens, growth hormone pens, and injection needles. Furthermore, it develops intelligent tools for diabetes management, including advanced smart insulin pens and the Dose Check application, designed to assist with insulin dosage guidance. The company holds a cooperative agreement with Aspen Pharmaceuticals for the manufacturing of insulin products. Novo Nordisk A/S was founded in 1923 and its corporate headquarters are located in Bagsvaerd, Denmark.
Novo Nordisk A/S is most often compared with the following Healthcare names: